CAR T developers plan steps to reach more indications

As CAR T developers take stock after the first wave of approvals, they are drawing a to-do list of what changes are needed to broaden the modality from its narrow indications and fully exploit its potential.

The problems span regulatory pathways, manufacturing processes and scientific innovation, and center on the slow pace of clinical development, the prohibitive manufacturing costs and the lack of tumor specific targets. Ultimately, they all contribute to the sluggish rate of bringing CAR T innovations to patients. ...